|
63 Companies |
|
72 Products |
|
72 Products |
|
71 Mechanisms of Action |
|
1 Trial |
|
335 News |
|
| 1234567» |
- | thiotepa / Generic mfg.
Trial completion: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - May 17, 2019
P2, N=44, Completed, Sponsor: Centre Leon Berard
Active, not recruiting --> Completed
- ||||| Trial completion, Metastases: Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma (clinicaltrials.gov) - Mar 13, 2019
P3, N=60, Completed, Sponsor: InSightec
Active, not recruiting --> Completed Recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination, Metastases: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer (clinicaltrials.gov) - Jan 18, 2019
P1, N=19, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision.
- | NN1213 / Novo Nordisk
Trial completion date, Trial termination, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Sep 19, 2018
P2, N=9, Terminated, Sponsor: Washington University School of Medicine
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. Trial completion date: May 2022 --> Aug 2017 | Active, not recruiting --> Terminated; Slow accrual
- | thiotepa / Generic mfg.
Trial primary completion date: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - Aug 23, 2018
P2, N=45, Active, not recruiting, Sponsor: Centre Leon Berard
Trial completion date: May 2022 --> Aug 2017 | Active, not recruiting --> Terminated; Slow accrual Trial primary completion date: Dec 2017 --> Dec 2018
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Surgery: GEIS: Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults (clinicaltrials.gov) - Aug 1, 2018
P2, N=43, Completed, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - Jun 29, 2018
P=N/A, N=15, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=90 --> 15
- ||| Trial completion date, Trial primary completion date, Metastases: Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma (clinicaltrials.gov) - Jun 14, 2018
P3, N=60, Recruiting, Sponsor: InSightec
Recruiting --> Completed | N=90 --> 15 Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Jan 2019
- | cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Apr 20, 2018
P2, N=46, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Jan 2018 --> Jan 2019 Active, not recruiting --> Completed
- | Trial withdrawal: A Vaccine Study for High Risk Cancers (clinicaltrials.gov) - Nov 24, 2017
P1, N=0, Withdrawn, Sponsor: Penn State University
Active, not recruiting --> Completed Terminated --> Withdrawn
- | Phase classification, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Nov 20, 2017
P1, N=1, Completed, Sponsor: Mayo Clinic
Terminated --> Withdrawn Phase classification: P=N/A --> P1
- | Phase classification, Trial primary completion date: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - Oct 6, 2017
P2, N=8, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P1 Phase classification: P1/2 --> P2 | Trial primary completion date: Jun 2015 --> May 2014
- | humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial completion, Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 17, 2017
P1, N=50, Completed, Sponsor: St. Jude Children's Research Hospital
Phase classification: P1/2 --> P2 | Trial primary completion date: Jun 2015 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 1, 2017
P1, N=113, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014 N=74 --> 113
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung (clinicaltrials.gov) - Jul 31, 2017
P1/2, N=19, Completed, Sponsor: Insmed Incorporated
N=74 --> 113 Recruiting --> Completed
- ||| Talzenna (talazoparib) / Pfizer
Trial completion, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Jul 18, 2017
P1, N=74, Completed, Sponsor: Medivation, Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Jun 23, 2017
P2, N=9, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=36 --> 9 | Trial primary completion date: Dec 2017 --> Aug 2017
- | Istodax (romidepsin) / Astellas, BMS
Trial completion, Trial initiation date, Trial primary completion date, Metastases: Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 14, 2017
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=36 --> 9 | Trial primary completion date: Dec 2017 --> Aug 2017 Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
- | Trial primary completion date: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - May 31, 2017
P=N/A, N=90, Recruiting, Sponsor: Duke University
Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 Trial primary completion date: Jun 2017 --> Jun 2018
- | dactinomycin / Generic mfg., vincristine / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Evaluating Dactinomycin and Vincristine in Young Patients With Cancer (clinicaltrials.gov) - May 17, 2017
P=N/A, N=158, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jun 2016
- | plerixafor / Generic mfg.
Trial completion, Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - May 16, 2017
P1/2, N=46, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jun 2016 Active, not recruiting --> Completed | N=30 --> 46
- | Biomarker, Trial primary completion date: Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma (clinicaltrials.gov) - May 8, 2017
P=N/A, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed | N=30 --> 46 Trial primary completion date: Feb 2017 --> Apr 2016
- | calcitriol (BPM 31543) / BPGbio
Trial completion, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - Apr 25, 2017
P1, N=30, Completed, Sponsor: Berg, LLC
Trial primary completion date: Feb 2017 --> Apr 2016 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=54, Completed, Sponsor: Wake Forest University Health Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2009
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial completion: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Apr 4, 2017
P1, N=54, Completed, Sponsor: Karyopharm Therapeutics Inc
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Oct 2009 Active, not recruiting --> Completed
- | Trial completion, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=9, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Jan 30, 2017
P2, N=36, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Dec 2017
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Completed
- Mepact (mifamurtide) / Takeda
Trial termination: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=25, Terminated, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Regulatory agency commitment fulfilled.
- calcitriol (BPM 31543) / BPGbio
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - Dec 22, 2016
P1, N=30, Active, not recruiting, Sponsor: Berg, LLC
Active, not recruiting --> Terminated; Regulatory agency commitment fulfilled. Recruiting --> Active, not recruiting | N=18 --> 30 | Trial primary completion date: Aug 2016 --> Jan 2017
- melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 6, 2016
P1, N=0, Withdrawn, Sponsor: University of Louisville
Recruiting --> Active, not recruiting | N=18 --> 30 | Trial primary completion date: Aug 2016 --> Jan 2017 N=10 --> 0 | Recruiting --> Withdrawn
- thiotepa / Generic mfg.
Enrollment closed, Enrollment change: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - Dec 2, 2016
P2, N=45, Active, not recruiting, Sponsor: Centre Leon Berard
N=10 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting | N=66 --> 45
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Oct 21, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting | N=66 --> 45 N=46 --> 30
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Oct 13, 2016
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=46 --> 30 Trial primary completion date: Jun 2015 --> Dec 2016
- decitabine / Generic mfg.
Trial completion: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Oct 6, 2016
P1, N=19, Completed, Sponsor: University of Louisville
Trial primary completion date: Jun 2015 --> Dec 2016 Active, not recruiting --> Completed
- sirolimus / Generic mfg.
Trial completion, Enrollment change: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Oct 4, 2016
P1, N=18, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 18
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment closed, Enrollment change: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Aug 19, 2016
P1, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | N=30 --> 18 Recruiting --> Active, not recruiting | N=75 --> 50
- ||| Biomarker, Trial completion, Trial primary completion date: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=1650, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting | N=75 --> 50 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- | Biomarker, Trial completion, Trial primary completion date: Biomarker in Tissue Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jul 12, 2016
P=N/A, N=40, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016
- Enrollment change, Trial termination, Trial primary completion date, HEOR, Surgery: Cyberknife Radiosurgery and Quality of Life (clinicaltrials.gov) - Jul 1, 2016
P=N/A, N=15, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jul 2016 N=70 --> 15 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Jun 2012
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Trial primary completion date: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Jun 5, 2016
P1, N=53, Active, not recruiting, Sponsor: Karyopharm Therapeutics, Inc
N=70 --> 15 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2012 --> Jun 2012 Trial primary completion date: Mar 2016 --> Jul 2016
- | Biomarker, Trial completion, Trial primary completion date: Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas (clinicaltrials.gov) - May 19, 2016
P=N/A, N=34, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2016 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial primary completion date: Study of Blood Samples From Patients With Osteosarcoma (clinicaltrials.gov) - May 19, 2016
P=N/A, N=1000, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial initiation date, Trial primary completion date: DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers (clinicaltrials.gov) - May 19, 2016
P=N/A, N=90, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Initiation date: Feb 2011 --> Apr 2010 | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial primary completion date: Study of Tumor Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - May 19, 2016
P=N/A, N=200, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Initiation date: Feb 2011 --> Apr 2010 | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed
- Biomarker, Enrollment change, Trial termination: Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma (clinicaltrials.gov) - May 10, 2016
P=N/A, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed N=24 --> 6 | Recruiting --> Terminated; Slow accrual and lack of funding
- Trial completion, Enrollment change: Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=950, Completed, Sponsor: University Hospital Muenster
N=24 --> 6 | Recruiting --> Terminated; Slow accrual and lack of funding Recruiting --> Completed | N=2200 --> 950
- Trial completion: Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=20, Completed, Sponsor: National Cancer Center, Korea
Recruiting --> Completed | N=2200 --> 950 Active, not recruiting --> Completed
- Trial termination: Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (clinicaltrials.gov) - Mar 16, 2016
P1/2, N=8, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated; Study was closed to enrollment before dose level one was completed.